Develops innovative drug candidates for metabolic and liver diseases. Conducts clinical trials to evaluate the safety and efficacy of its products. Now — the numbers.
This is an established company with proven profits.
Average growth of 206% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $22.8M would still be left in the vault — a solid cushion for hard times.
The market pays 254.9× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 45% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 206% a year on average.
There is $94.9M in the vault; even if every debt were paid off, $22.8M would remain.
The company’s market value is 255 times its annual profit. Even a small disappointment could hit the price hard.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.